Description of Business and Basis of Presentation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended		3 Months Ended	12 Months Ended
	Jun. 17, 2021	Jul. 31, 2021	Apr. 30, 2021	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Mar. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Net proceeds from the issuance of common stock					$ 138	$ 148,732
Retained earnings accumulated deficit					(291,628)	(213,632)
Non-current marketable debt securities					16,793	0
Cash and cash equivalents					55,610	170,064
Redeemable non-controlling interest equity redemption value							$ 43,400
Gain (Loss) on Extinguishment of Debt			$ 300
Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests			15,700
Fair Value, Option, Changes in Fair Value, Gain (Loss)					0	(3,903)
Payments to Noncontrolling Interests			$ 21,000		0	$ 20,966
Shangai Ambrx Biopharma Co Ltd [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners			11.00%
Liquidity and Capital Resources [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Retained earnings accumulated deficit					291,600
Cash and cash equivalents and marketable debt securities					101,300
Non-current marketable debt securities					$ 16,800
ADR [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Stock shares issued during the period shares	7,000,000
Sale of stock issue price per share	$ 18.00
IPO [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Net proceeds from the issuance of common stock	$ 113,200
Stock issuance costs incurred underwriting discounts and commissions	8,800
Stock Issuance Costs Incurred Professional Fees	$ 4,000
Conversion of temporary equity into permanent equity shares	193,511,558
Over-Allotment Option [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Stock shares issued during the period shares		892,831
Net proceeds from the issuance of common stock		$ 14,900
Sale of stock issue price per share		$ 18.00
Additional Paid-in Capital [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Derivative Assets (Liabilities), at Fair Value, Net			$ 26,300
Shangai Ambrx Biopharma Company Limited [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Equity method investment ownership percentage					100.00%
Note payment			$ 190,000	$ 24,000
Stock shares issued during the period shares			2,004,879
Net proceeds from the issuance of common stock			$ 2,100
Loan Settlement and Capital Reduction				$ 166,000	$ 166,000
Fees and interest					1,000
Redeemable non-controlling interest equity redemption value					$ 36,000		$ 36,700
Payments to Noncontrolling Interests			$ 21,000
Biolaxy Pharmaceutical Hongkong Limited [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Equity method investment ownership percentage					100.00%
Ambrx US [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Equity method investment ownership percentage					100.00%
Ambrx Austrailia Pty Limited [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Equity method investment ownership percentage					100.00%